<DOC>
	<DOCNO>NCT01327703</DOCNO>
	<brief_summary>This study Aptalis ( formerly Axcan ) assess efficacy safety Panzytrat® 25,000 compare Kreon® 25,000 control steatorrhea participant cystic fibrosis ( CF ) exocrine pancreatic insufficiency ( EPI ) .</brief_summary>
	<brief_title>Control Steatorrhea Participants With Cystic Fibrosis Exocrine Pancreatic Insufficiency</brief_title>
	<detailed_description>This open-label , Phase IV , multicenter , randomize , two-period cross-over study compare efficacy safety Panzytrat® 25,000 Kreon® 25,000 participant age 7 year old suffer CF EPI . The study consist qualification phase ( 5 15 day ) ; two treatment period 14 day ( plus 3-day window need ) 3-day stool collection perform Days 12 15 . A safety follow-up phone call arrange 7-10 day completion treatment phase early discontinuation .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<mesh_term>Steatorrhea</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<criteria>Participant his/her legal representative sign informed consent form ( ICF ) prior start study procedure Participant clinical diagnosis CF base one typical clinical feature CF phenotype , addition one following : genotype document presence 2 CFcausing mutation , sweat chloride test great equal 60 millimole per liter ( mmol/L ) quantitative pilocarpine iontophoresis two separate occasion Participant severe EPI confirm enzymelinked immunosorbent assay ( ELISA ) measurement fecal elastase1 ( FE1 ) Male female participant age 7 year old Participant currently receive receive stable dose lipase either Panzytrat® 25,000 Kreon® 25,000 least 30 day prior ICF signature Participant generally good health , except underlie symptom associate CF EPI , clinically stable ( change last 30 day physical examination ) evidence medical medication history , physical examination include vital sign screen laboratory test Participant able maintain CF standardize diet lipid content customize his/her need study accord qualification phase diary Women childbearing potential must negative pregnancy test study entry must use medically acceptable contraceptive method duration study Participant know contraindication , sensitivity hypersensitivity Panzytrat® 25,000 Kreon® 25,000 , porcine protein Participant recently receive treatment emergent acute infection oral intravenous ( IV ) antibiotic stop least 14 day prior randomization Participant chronic use narcotic stop least 7 day prior qualification visit Participant use prohibit medication product list prohibited medication section protocol Participant acute pancreatitis exacerbation chronic pancreatic disease Participant history significant bowel resection could impair fat absorption Participant condition know increase fecal fat loss include limited : celiac disease , Crohn 's disease , tropical sprue , bacterial bowel infection , liver disease , lactose intolerance , pseudomembranous colitis , biliary pancreatic cancer , radiation enteritis , Whipple 's disease , Whipple 's procedure , etc Participant significant gastrointestinal dysmotility disorder Participant chronic abdominal pain severe abdominal pain study entry Participant use enteral tube feed day night Participant history presence clinically significant portal hypertension Participant history presence complete distal intestinal obstruction syndrome ( DIOS ) past 6 month , 2 episode DIOS past year Participant poorly control diabetes per investigator 's opinion Female participant pregnant breastfeed Participant condition history illness , prestudy laboratory abnormality , opinion investigator sponsor , might put participant risk , prevent participant complete study , otherwise affect outcome study Participant use investigational drug within 30 day prior date signature ICF</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Exocrine Pancreatic Insufficiency</keyword>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>Steatorrhea</keyword>
	<keyword>Malabsorption</keyword>
	<keyword>Malnutrition</keyword>
</DOC>